ArticleNeurology and therapy2026
Access to Neurology Healthcare Professionals in the United States Among Patients With Epilepsy Using Medicaid: A Retrospective, Observational, Claims-Based Analysis.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis retrospective, longitudinal, observational study of claims data assessed provider access barriers among patients (aged ≥ 18 years) with epilepsy enrolled in Medicaid in the United States.
methodsRecords of patients with ≥ 1 epilepsy diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes: 345.4/345.40/345.41/345.5/345.50/345.51/345.7/345.70/345.71; ICD-10-CM codes: G40.0/G40.1/G40.2/G40.5) or ≥ 2 diagnoses for unspecified convulsions (ICD-9-CM: 780.39; ICD-10-CM: R56.9) on different days (≤ 12 months apart) in STATinMED's RWD Insights all-payer claims database (1/1/2014-6/30/2021) were identified. Patients using Medicaid with ≥ 1 antiseizure medication (ASM) prescription (date of first ASM prescription = index date) on/after initial diagnosis and continuous capture of medical and pharmacy benefits for 12 months before the index date (baseline) and 12 months after and including the index date (follow-up) were included. Proximity to and use of neurology healthcare professionals (HCPs; neurology HCP = neurologist or neuropsychiatrist) for epilepsy-related care during the 12-month follow-up were assessed.
resultsThe study included 24,722 patients (mean age: 43.3 years, female: 62.4%). Index ASM was prescribed mostly by HCPs who typically provide primary care (family practice/internal medicine physicians/nurse practitioners/physician assistants; 42.2%). During follow-up, > 85% of patients were using any second-generation ASMs, while 71.3% of patients had no access to an epilepsy-treating neurology HCP in proximity to their home. Access to an epilepsy-treating neurology HCP in proximity to home was more common among patients who resided in urban areas [30.3% (n = 6817/22,519)] than patients living in rural areas [12.6% (n = 278/2203)].
conclusionsMost patients with epilepsy using Medicaid, particularly those living in rural areas, did not have access to neurology HCPs in proximity to their home, suggesting challenges to receiving optimal care. Graphical abstract available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.